Arcutis Biotherapeutics
ARQT
133 hedge funds and large institutions have $347M invested in Arcutis Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 50 increasing their positions, 25 reducing their positions, and 40 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 25
4.81% more ownership
Funds ownership: 108.94% → 113.75% (+4.8%)
1% more call options, than puts
Call options by funds: $562K | Put options by funds: $557K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 40
1% less funds holding
Funds holding: 134 → 133 (-1)
3% less capital invested
Capital invested by funds: $357M → $347M (-$9.94M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$32.5M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$19.9M |
| 3 |
Jennison Associates
New York
|
+$12.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$9.14M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$8.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.1M |
| 2 |
O
OrbiMed
New York
|
-$10.2M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.71M |
| 4 |
Holocene Advisors
New York
|
-$6.4M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$6.02M |
ARQT Hedge Fund Activity: Q4 2023 in Review
133 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q4 2023, worth a combined $347M — down 2.8% from $357M a quarter earlier.
Fund positioning in ARQT was balanced in Q4 2023: 40 funds opened new positions, 40 closed out, 50 added to existing stakes and 25 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $32.5M. The largest seller was Fidelity Investments, cutting an estimated $19.1M.
- 133 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q4 2023, down from 134 in Q3 2023.
- Funds reported $347M of Arcutis Biotherapeutics stock for Q4 2023, down 2.8% quarter-over-quarter.
- 40 funds opened new Arcutis Biotherapeutics positions in Q4 2023 and 40 closed out, a net change of 0 holders.
- The largest Arcutis Biotherapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $32.5M added.
- The largest Arcutis Biotherapeutics seller in Q4 2023 was Fidelity Investments, an estimated $19.1M sold.
Based on aggregated 13F filings for Q4 2023.